Company Overview

Shoulder Innovations, Inc. (SI) is a privately held medical technology company focused on the design, development, and commercialization of shoulder replacement systems and related surgical technologies for orthopedic care. The company operates within the orthopedic medical device industry, specifically the shoulder arthroplasty and extremities segment, serving orthopedic surgeons, ambulatory surgery centers, and hospital systems that perform shoulder reconstruction procedures. SI’s primary products include shoulder replacement implants and enabling surgical technologies intended to improve procedural efficiency, implant positioning, and clinical reproducibility in total shoulder arthroplasty procedures.

The company is best known for its InSet™ Glenoid technology and associated shoulder arthroplasty platform, which are designed to address implant fixation, bone preservation, and surgical workflow considerations. SI has positioned itself as a specialized shoulder-focused company rather than a broad orthopedic implant manufacturer, differentiating itself through surgeon-driven product development and a concentrated portfolio strategy. Founded in the United States by orthopedic surgeon and entrepreneur Dr. Robert Tashjian along with industry executives and engineers experienced in orthopedic devices, the company evolved from a clinical and engineering effort to improve shoulder replacement outcomes and procedural simplicity.

Business Operations

Shoulder Innovations generates revenue primarily through the sale of shoulder arthroplasty implants, associated instrumentation, and enabling surgical technologies. Its operations are centered on the commercialization of shoulder replacement systems, including anatomic and reverse shoulder arthroplasty solutions. The company’s core commercial platform includes the InSet™ Shoulder System, which integrates implant components and procedural tools intended to support implant fixation and simplify surgical implantation. SI’s business model relies heavily on surgeon adoption, distributor relationships, clinical education, and procedural utilization growth within orthopedic practices and hospital networks.

The company primarily operates in the United States, though it has pursued broader international expansion opportunities through distribution partnerships and regulatory initiatives. SI controls proprietary implant designs, intellectual property related to glenoid fixation and implant geometry, and associated surgical instrumentation technologies. Publicly available information indicates that the company has collaborated with orthopedic surgeons, healthcare institutions, and distribution partners to support product adoption and surgeon training. Data regarding major joint ventures or large-scale international subsidiaries is inconclusive based on available public sources.

Strategic Position & Investments

Shoulder Innovations’ strategic direction has focused on expanding its shoulder arthroplasty portfolio, increasing surgeon adoption, and strengthening its position in the growing shoulder replacement market. The company has emphasized innovation in implant fixation, surgical efficiency, and procedural reproducibility as central growth initiatives. SI has also invested in surgeon education programs, commercialization infrastructure, and product development initiatives intended to support broader procedural adoption in both hospital and outpatient surgical settings.

The company has raised institutional growth capital from healthcare-focused investors to support commercialization and product expansion efforts. Public announcements and investment disclosures indicate backing from medical technology and private equity investors, including funding rounds aimed at scaling manufacturing, sales operations, and research and development capabilities. SI’s strategic focus aligns with broader orthopedic industry trends favoring outpatient procedures, minimally invasive workflows, and specialized extremities platforms. Information regarding acquisitions or a diversified subsidiary portfolio remains limited in publicly available disclosures.

Geographic Footprint

Shoulder Innovations is headquartered in Grand Rapids, Michigan, a region with a significant orthopedic manufacturing and medical device ecosystem. The company’s principal commercial presence is concentrated in the United States, where it markets shoulder arthroplasty systems to orthopedic surgeons and healthcare providers. Its commercial efforts have targeted major orthopedic markets and high-volume shoulder reconstruction centers across multiple U.S. regions.

The company has also indicated interest in broader international expansion through distributor relationships and regulatory pathways outside the United States, although detailed operational disclosures for specific international markets are limited. Publicly available information suggests growing visibility within the broader North American orthopedic sector, with emerging interest in additional international orthopedic markets. Data regarding the scale of direct international operations is inconclusive based on available public sources.

Leadership & Governance

Shoulder Innovations was founded with participation from orthopedic surgeon innovators and experienced medical device executives focused on advancing shoulder arthroplasty technologies. The company’s leadership strategy has emphasized surgeon-centric innovation, focused product specialization, and operational scaling within the orthopedic implant sector. Public communications from management have consistently highlighted procedural efficiency, clinical outcomes, and surgeon usability as core strategic priorities.

Key executives associated with the company include:

• Todd Littooy – Chief Executive Officer
• Dr. Robert Tashjian – Founder and Chief Medical Officer
• Michael Dill – Chief Commercial Officer
• Brandon Rouw – Chief Financial Officer
• Aaron Krych – Senior executive leadership roles reported in company materials and commercialization activities

Leadership and governance information has been verified against company announcements, investor communications, and industry reporting. Certain executive role details may change over time due to the company’s private status and limited public filing requirements.